• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    2/13/24 5:02:29 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CORT alert in real time by email
    SC 13G/A 1 tv0680-corcepttherapeuticsin.htm SCHEDULE 13G/A corcepttherapeuticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 8)*

    Name of issuer:  Corcept Therapeutics Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  218352102

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  218352102

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    149,122

    7.  SOLE DISPOSITIVE POWER

    9,296,649

    8.  SHARED DISPOSITIVE POWER

    240,883

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,537,532

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.25%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Corcept Therapeutics Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    149 Commonwealth Drive
    Menlo Park, CA 94025

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    218352102

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CORT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CORT

    DatePrice TargetRatingAnalyst
    11/6/2023$29.00 → $38.00Hold → Buy
    Truist
    4/11/2023$25.00Market Perform
    SVB Securities
    4/4/2023$27.00Overweight
    Piper Sandler
    2/15/2023$35.00 → $22.00Buy → Hold
    Jefferies
    8/1/2022$30.00Buy → Hold
    Truist
    7/27/2022$21.00 → $35.00Hold → Buy
    Jefferies
    6/27/2022$30.00 → $34.00Buy
    Canaccord Genuity
    2/2/2022$30.00Buy
    Canaccord Genuity
    More analyst ratings

    $CORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

    Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting. The data, which will be presented in a late-breaking oral presentation on Sunday, October 19, 2025, focuses on trial participants who were previously treated with a PARP inhibitor, a patient population with particular

    9/22/25 2:30:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

    FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has accepted Corcept's New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. The FDA has assigned a PDUFA date of July 11, 2026 for the application. Corcept's NDA is based on positive data from its pivotal Phase 3 ROSELLA and Phase 2 tr

    9/10/25 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

    Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidance of $850 – $900 million Net income of $35.1 million, compared to $35.5 million in second quarter 2024 Cash and investments of $515.0 million at June 30, 2025 Acquired $115.4 million of Corcept common stock in second quarter 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results

    7/31/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Guyer William gifted 200 shares, decreasing direct ownership by 4% to 5,287 units (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    9/23/25 5:06:36 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cannon Gillian gifted 7,393 shares, closing all direct ownership in the company (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    9/11/25 9:03:44 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Swisher Daniel N Jr exercised 2,200 shares at a strike of $14.08 and sold $159,390 worth of shares (2,200 units at $72.45) (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    9/11/25 8:38:43 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    SEC Filings

    View All

    SEC Form 8-K filed by Corcept Therapeutics Incorporated

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    9/10/25 8:09:04 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Corcept Therapeutics Incorporated

    10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    7/31/25 4:10:44 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    7/31/25 4:07:42 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Corcept Therapeutics upgraded by Truist with a new price target

    Truist upgraded Corcept Therapeutics from Hold to Buy and set a new price target of $38.00 from $29.00 previously

    11/6/23 7:25:25 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Securities initiated coverage on Corcept Therapeutics with a new price target

    SVB Securities initiated coverage of Corcept Therapeutics with a rating of Market Perform and set a new price target of $25.00

    4/11/23 7:25:02 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Corcept Therapeutics with a new price target

    Piper Sandler initiated coverage of Corcept Therapeutics with a rating of Overweight and set a new price target of $27.00

    4/4/23 7:17:46 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Leadership Updates

    Live Leadership Updates

    View All

    $CORT
    Financials

    Live finance-specific insights

    View All

    $CORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Corcept Appoints Roberto Vieira as President, Oncology

    MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o

    1/29/24 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Appoints Monica Tellado as President, Emerging Markets

    MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science

    11/1/23 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Appointment of Three Senior Leaders

    MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid

    4/7/22 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

    Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidance of $850 – $900 million Net income of $35.1 million, compared to $35.5 million in second quarter 2024 Cash and investments of $515.0 million at June 30, 2025 Acquired $115.4 million of Corcept common stock in second quarter 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results

    7/31/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 31, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therapeut

    7/24/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

    Revenue of $157.2 million, compared to $146.8 million in first quarter 2024 Reiterated 2025 revenue guidance of $900 – $950 million Net income per common share (diluted) of $0.17, compared to $0.25 in first quarter 2024 Cash and investments of $570.8 million as of March 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat serious endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2025. Financial Results "In the first quarter, we had another record number of prescrip

    5/5/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    3/27/24 2:32:52 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    2/14/24 4:23:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    2/13/24 5:02:29 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care